Indications
Symptomatic treatment of mild to moderately severe Alzheimer's dementia.
Composition
- Active substance
- rivastigmine
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Rivastigmine 3M Health Care Ltd
- Active substance
- rivastigmine
- ATC code
- N06DA03
- Group
- Nervous system
- Therapeutic area
- Alzheimer Disease
- Marketing authorisation holder
- 3M Health Care Limited
- Status
- Withdrawn
- EU authorisation
- 3 Apr 2014
- Withdrawn
- 19 Aug 2014